192 related articles for article (PubMed ID: 18716616)
1. Imaging as a tumor biomarker in oncology drug trials for lung cancer: the FDA perspective.
Petrick N; Brown DG; Suleiman O; Myers KJ
Clin Pharmacol Ther; 2008 Oct; 84(4):523-5. PubMed ID: 18716616
[TBL] [Abstract][Full Text] [Related]
2. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
3. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
4. FDA Oncology Committee debates Iressa's status following negative trial results.
Twombly R
J Natl Cancer Inst; 2005 Apr; 97(7):473. PubMed ID: 15812066
[No Abstract] [Full Text] [Related]
5. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
6. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
7. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
8. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
9. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
10. The seamless approach to drug development in oncology.
Pazdur R
Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
[No Abstract] [Full Text] [Related]
11. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
Blumenthal GM; Goldberg KB; Pazdur R
Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
[TBL] [Abstract][Full Text] [Related]
12. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
13. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
14. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.
Printz C
Cancer; 2015 May; 121(10):1529-30. PubMed ID: 25946212
[No Abstract] [Full Text] [Related]
15. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
16. FDA starts moving on critical path, but initiative running out of steam.
Finkelstein JB
J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
[No Abstract] [Full Text] [Related]
17. From serendipity to design: the evolution of drug development in oncology.
Markman M; Peereboom DM
Cleve Clin J Med; 1997 Mar; 64(3):155-63. PubMed ID: 9068226
[TBL] [Abstract][Full Text] [Related]
18. FDA announces fast track approval of new drug for lung cancer.
Dyer O
BMJ; 2003 May; 326(7397):1004. PubMed ID: 12742913
[No Abstract] [Full Text] [Related]
19. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
20. Development of public resources to support quantitative imaging methods in cancer.
Clarke LP; Croft B
Acad Radiol; 2007 Dec; 14(12):1438-40. PubMed ID: 18035273
[No Abstract] [Full Text] [Related]
[Next] [New Search]
